Please assess the completion status of the following clinical trial:

Trial Title: Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma in first or second complete or partial remission~* \>= 4 weeks since last cycle of chemotherapy (thalidomide, dexamethasone, and Velcade were not considered prior chemotherapy for the purpose of this study)~* Recovered from all acute toxic effects of prior chemotherapy~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* White Blood Cell count (WBC) \> 2.5\*10\^9/L~* Absolute polymorphonuclear leukocytes (PMN) count \> 1.5\*10\^9/L~* Platelet (PLT) \> 100\*10\^9/L~* Serum creatinine \<=2.2 mg/dL~* Cardiac and pulmonary status sufficient to undergo apheresis and transplantation~* Negative for HIV~Exclusion Criteria):~* Failed previous stem cell collection~* Previous stem cell transplantation~* Brain metastases or myelomatous meningitis~* Radiation to ≥ 50% of the pelvis~* Abnormal electrocardiogram (ECG) with rhythm disturbance (ventricular arrhythmias) or other conduction abnormality~* Received bone-seeking radionuclides (e.g. holmium)~* A residual acute medical condition resulting from prior chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- G-CSF plus plerixafor (Type: EXPERIMENTAL): None
- G-CSF plus placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).